Cancer Research

Scientists engineer new cancer immunotherapy to train immune system in cancer fight

2 November 2020

A new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumour cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell. This nanobiologic immunotherapy […]

Cancer Research UK collaboration will identify oncology innovation

2 November 2020

The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park with funding from Innovate UK and Cancer Research UK A collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight and expertise to nurture them […]

Mission Bio launches single-cell multi-omics system for precision cancer therapies

30 October 2020

Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half. The company […]

New drug for difficult-to-drug cancer mutation could be key treatment for other cancers

29 October 2020

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows. Researchers used an innovative, intermittent treatment schedule to limit the drug’s toxicity, and found responses in over a […]

US biotech start-up set to have huge impact on breast cancer treatment landscape

28 September 2020

Backed by more than 20 years of research and development expertise, Concarlo Holdings is developing diagnostics and therapeutics that could have huge impact for metastatic breast cancer patients. Lu Rahman finds out more. Stacy Blain, Co-Founder, Concarlo Holdings, wants to change the conversation around breast cancer. This biotechnology start-up whose technologies aim to diagnose and […]

Flipping a metabolic switch to slow tumour growth

14 August 2020 , By Christian Metallo

The enzyme serine palmitoyl-transferase can be used as a metabolically responsive ‘switch’ that decreases tumour growth. This is according to a new study by a team of San Diego scientists, who published their findings in the journal Nature. By restricting the dietary amino acids serine and glycine, or pharmacologically targeting the serine synthesis enzyme phosphoglycerate dehydrogenase, […]

Pre-existing immune-resistant cancer cells identified in melanoma

10 August 2020 , by Daniel Peeper

Researchers at the Netherlands Cancer Institute have discovered a cluster of tumour cells that are refractory to immunotherapy and that exists even prior to treatment. This finding, which was published in the scientific journal Nature Communications, may lead to new therapies that eliminate cancer more effectively. The research group, led by Daniel Peeper, focused on melanoma, […]

Orphan Drug Designation granted to tinostamustine for rare form of leukaemia

7 August 2020 , By Brian Sheehan

Tinostamustine is in early phase clinical trials (Phase I) to investigate its use as a potential future treatment option in this area of significant unmet patient need. Mundipharma has revealed  that the European Commission (EC) has adopted the European Medicines Agency (EMA) Committee for Orphan Medicinal Products recommendation to grant Orphan Drug Designation (ODD) to tinostamustine, […]

Cancer Research UK collaborate to develop head and neck cancer vaccine

5 August 2020 , DDW editorial

This a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC) HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst existing immunotherapies […]

Drug target for aggressive breast cancer found

5 August 2020 , by Dr Bruno Simões and Professor Rob Clarke

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers. Around three quarters of […]

Researchers discover cell communication mechanism that drives cancer adaptation

5 August 2020 , By Professor Deborah Goberdhan, Professor Clive Wilson and Professor Adrian Harris

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins, RNAs and other molecules, which can re-programme […]

Collaboration to investigate IMM-101 in difficult to treat cancers

3 August 2020 , DDW editorial

This will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma. Immodulon, an immuno-oncology company, and the Champalimaud Foundation, a private, non-profit, research organisation in Lisbon, Portugal, have announced research intended to examine the potential use […]

Merging two immunotherapies may be more effective treatment against some cancers

29 July 2020 , by Julia Evangelou Strait

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies […]

Researchers ID new target in drive to improve immunotherapy for head and neck cancer

29 July 2020 , By Dr. Cun-Yu Wang

Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor […]

Immune system could be trained to spot drug-resistant cancers

24 July 2020 , DDW editorial

Aggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer cells with specific drug resistance-causing mutations, a major new study suggests. Drug resistance mutations which restore activity of the BRCA1 or BRCA2 genes as a way of avoiding the effects of drug treatment could leave tumours vulnerable to the effects […]

« Previous

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free